Supplementary Material

Inhibitor Screening using Immobilized Enzyme-Reactor Chromatography/Mass Spectrometry

Richard J. Hodgson, Travis R. Besanger, Michael A. Brook and John D. Brennan*

Department of Chemistry, McMaster University, 1280 Main St. West, Hamilton, ON, L8S 4M1

*Author to whom correspondence should be addressed

Tel: (905) 525-9140 (ext. 27033)

Fax: (905) 527-9950

e-mail: brennanj@mcmaster.ca

internet: http://www.chemistry.mcmaster.ca/faculty/brennan

LC/MS Settings

Specific MS/MS parameters for each ion pair are shown in Table S1. The total scan time was 2 seconds per point.

Table S1

| Species | Q1 (m/z) | Q3 (m/z) | Time (ms) | DP (V) | EP (V) | CE (V) | CXP (V) |
|-----------|----------|----------|-----------|--------|--------|--------|---------|
| Adenosine | 268 | 136 | 495 | 66 | 6.8 | 29.4 | 3.3 |
| Inosine | 269 | 137 | 495 | 49 | 4.0 | 22.0 | 4.0 |
| EHNA* | 278 | 119 | 495 | 90 | 10.0 | 52.0 | 4.0 |
| EHNA | 278 | 136 | 495 | 90 | 10.0 | 52.0 | 4.0 |

*Note: The weaker signal from this EHNA ion-pair was not used for data analysis but it's presence in

the MRM method leads to a total scan time of 2 seconds, including 20 msec pause.

Compounds Tested:

| # | Name |
|----|---------------------------------------|
| 1 | (-)- Sulpiride |
| 2 | (-)- Butaclamol.HCl |
| 3 | Haloperidol |
| 4 | 4-Nitrophenethyl bromide |
| 5 | Spiperone |
| 6 | L-glutamicacid-y-(p-nitroanilide).HCl |
| 7 | Dipyridamol |
| 8 | ATP |
| 9 | Glybenclamide |
| 10 | Glipizide |
| 11 | Benzamidine.HCl |
| 12 | Dextromethorphan.HBr |
| 13 | Pyrimethamine |
| 14 | N-Acetyl-L-Tryptophanamide |
| 15 | Trimethoprim |
| 16 | XTT.Na |
| 17 | Deoxycholic acid |
| 18 | 2-Fluoro-2'-deoxyadenosine |
| 19 | Carbamylcholine.Cl |
| 20 | Chloropromazine.HCl |
| 21 | Acetopromazine.maleate |

| 22 | Nα-Benzoyl-DL-Arginine-p-nitroanalide |
|----|---|
| 23 | p-nitrophenyl butyrate |
| 24 | 7-chloro-4-nitrobenz-2-oxa-1,3-diazole |
| 25 | N-benzoyl-L-Tyrosine ethyl ester |
| 26 | Acetaminophen |
| 27 | Caffeine |
| 28 | 7-Azaindole |
| 29 | Cytidine 2':3'-cyclic monophosphate.Na |
| 30 | Nɛ-Acetyl-L-lysine |
| 31 | Acetylcholine.Cl |
| 32 | (+)- Tubocurarine.Cl |
| 33 | Uridine 5'-diphospho-n-acetyl glucosamine |
| 34 | Phospho(enol)pyruvate.K |
| 35 | (-)- Nicotine.H-tartarate |
| 36 | Adenine |
| 37 | Gly-gly |
| 38 | 1,10-phenanthroline |
| 39 | EHNA |
| 40 | Sarcosine |
| 41 | Indole |
| 42 | Betaine |
| 43 | Trifluoperazine dihydrochloride |
| 44 | Activicin |
| 45 | p-nitrophenyl acetate |
| 46 | Guanylyl (2'-5') cytidine.NH ₄ |
| 47 | Acetylthiocholine.Cl |
| 48 | DL-Azatryptophan |
| 49 | +/- Epibatidine.2HCl |

Relationship between IC₅₀ and K_I:

The $K_{\rm I}$ value was determined by extrapolation of IC_{50} values to the point of zero substrate concentration, as shown in Figure 6b. The basis of this method is as follows, and is based on the derivation described by Cheng and Prusoff (ref 19).

The Michaelis-Menten equation is given by:

$$V_o = \frac{V_{\max}[S]}{K_m + [S]}$$

where V_0 is the initial rate of the enzyme catalyzed reaction. In the presence of a competitive inhibitor with an inhibition constant K_1 and a concentration [*I*], the rate of reaction will be reduced to V_1 :

$$V_I = \frac{V_{\max}[S]}{K_m(1 + \frac{[I]}{K_i}) + [S]}$$

By definition, if [*I*] is equal to IC_{50} then $V_I = \frac{1}{2}V_0$ and hence:

$$\frac{V_{\max}[S]}{K_m + [S]} = \frac{2V_{\max}[S]}{K_m (1 + \frac{IC_{50}}{K_i}) + [S]}$$

Rearranging and solving for IC_{50} :

$$\frac{1}{K_m + [S]} = \frac{2}{K_m (1 + \frac{IC_{50}}{K_i}) + [S]}$$
$$\therefore K_m (1 + \frac{IC_{50}}{K_i}) + [S] = 2K_m + 2[S]$$
$$\therefore K_m (1 + \frac{IC_{50}}{K_i}) = 2K_m + [S]$$
$$\therefore 1 + \frac{IC_{50}}{K_i} = 2 + \frac{[S]}{K_m}$$
$$\therefore \frac{IC_{50}}{K_i} = 1 + \frac{[S]}{K_m}$$
$$\therefore IC_{50} = K_i (1 + \frac{[S]}{K_m})$$

Rearranged in the form of a linear equation:

$$IC_{50} = K_i + \frac{K_i[S]}{K_m}$$
$$\therefore IC_{50} = \frac{K_i}{K_m}[S] + K_i$$

Hence in a plot of IC₅₀ vs [S], the slope is K_i/K_m , the y-intercept is K_i , and the negative x-intercept is – K_m . Note that for the enzyme reactor column, product concentration, rather than reaction rate, is monitored. Thus, the equation will be valid only under conditions where the initial rate is proportional

to product concentration. As noted in the text, for our system conversions of 30% or less lead to errors of 7% or less in estimation of rate data from product concentrations.



K_m value in solution

Figure S1. Assessment of K_m values for ADA in solution using an absorbance-based assay as described in reference 16. K_m was determined to be 89 μ M.